Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on asymmetric hydrogenation. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Patent CN113999084A details a novel asymmetric synthesis of (S)-nicotine via myosmine reduction, offering high purity and cost-effective manufacturing for reliable suppliers.
Patent CN115611716B reveals a novel synthesis route for high-purity chiral spirocyclic diphenols, offering significant cost reduction and supply chain reliability for pharmaceutical manufacturing.
Novel hydrogenation process reduces noble metal usage and improves purity for sitagliptin manufacturing, offering significant cost and supply chain advantages.
Discover CN101983186B technology for asymmetric hydrogenation. Enables cost reduction in pharmaceutical intermediate manufacturing with high stereoselectivity.
Patent CN112409235A details a Rh-catalyzed asymmetric hydrogenation route for chiral 4-halogenated tryptophan derivatives with 99.9% ee, offering a scalable solution for API intermediates.
Patent CN101921229B details a novel asymmetric catalytic hydrogenation route for L-Stepholidine. Discover cost-effective, scalable manufacturing solutions for high-purity pharmaceutical intermediates.
Patent CN109096329B details a novel asymmetric transfer hydrogenation for chiral beta-hydroxy phosphates, offering cost-effective routes for pharmaceutical intermediates.
Patent CN115286504B details asymmetric hydrogenation for brivaracetam intermediate. Delivers high purity and supply chain stability for global pharmaceutical manufacturing.
Patent CN113999201A details a novel asymmetric synthesis of S-nicotine, offering high purity and cost efficiency for pharmaceutical intermediate manufacturing.
Patent CN110724164B details novel pyridine-substituted spiro ligands enabling high TON hydrogenation. Ideal for API intermediates.
Novel Rh-catalyzed asymmetric hydrogenation avoids resolution, boosting yield to 42.55% for reliable API intermediate supply.
Patent CN112675920B reveals a novel Ruthenium catalyst for efficient chiral alcohol synthesis. Discover cost reduction in pharmaceutical intermediate manufacturing and scalable production methods.
Patent CN112675920B reveals a novel monochiral ruthenium catalyst enabling efficient asymmetric hydrogenation and kinetic resolution for high-purity pharmaceutical intermediates.
Patent CN110724164B discloses novel 3-substituted spiro ligands achieving 99% ee. Enables cost-effective API intermediate manufacturing with high TON.
Patent CN111793017B reveals Ru-catalyzed asymmetric hydrogenation for lactam intermediates. Offers high purity, safety without hydrogen gas, and scalable pharma manufacturing solutions.
Patent CN116715699B reveals manganese-based asymmetric hydrogenation. Offers cost reduction and supply reliability for pharmaceutical intermediates manufacturing.
Novel chiral bidentate nitrogen phosphine ligand Rong-Phos iridium complex for asymmetric hydrogenation. High purity pharmaceutical intermediates supplier with cost-effective synthesis.
Novel iron-catalyzed asymmetric hydrogenation technology using chiral quinoline imidazoline ligands. Reduces noble metal dependency for high-purity pharmaceutical intermediates.
Discover advanced ferrocene-based PNN ligands from patent CN114644663A for high-efficiency ketone hydrogenation, offering reliable supply and cost-effective pharma intermediate manufacturing.
Patent CN113195460A details enantioselective iridium-catalyzed hydrogenation of oximes. This breakthrough offers cost reduction in agrochemical intermediate manufacturing and reliable supply chain solutions.